Emergency treatment with nifekalant, a novel class III anti-arrhythmic agent, for life-threatening refractory ventricular tachyarrhythmias: Post-marketing special investigation

Circulation Journal

Volumn 69, Issue 10, 2005, Pages 1237-1243

  Katoh, Takao ^a,d   Mitamura, Hideo ^b   Matsuda, Naoki ^c   Takano, Teruo ^a   Ogawa, Satoshi ^a,b   Kasanuki, Hiroshi ^c  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KEIO UNIVERSITY   (Japan)

^c TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^d NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Antiarrhythmic drug; Life threatening ventricular arrhythmia; Nifekalant; QT prolongation

Indexed keywords

ANTIARRHYTHMIC AGENT; CATECHOLAMINE; NICORANDIL; NIFEKALANT;

ADULT; AGED; ARTICLE; ATRIOVENTRICULAR BLOCK; BRADYCARDIA; CARDIOMYOPATHY; CARDIOVERSION; DIRECT CURRENT; DRUG EFFICACY; DRUG INFUSION; DRUG USE; EMERGENCY TREATMENT; FEMALE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HEMODYNAMICS; HUMAN; KIDNEY DISEASE; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; PARAMETER; PAROXYSMAL TACHYCARDIA; PATIENT; POSTMARKETING SURVEILLANCE; QT INTERVAL; QT PROLONGATION; RECURRENT DISEASE; SINUS ARREST; SINUS BRADYCARDIA; TORSADE DES POINTES;

AGED; ANTI-ARRHYTHMIA AGENTS; EMERGENCY MEDICAL SERVICES; FEMALE; HUMANS; MALE; MARKETING; MIDDLE AGED; PYRIMIDINONES; TORSADES DE POINTES; VENTRICULAR FIBRILLATION;

EID: 25644452743     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.69.1237     Document Type: Article

References (13)

1. Kamiya J, Ishii M, Katakami T. Antiarrhythmic effects of MS-551, a new class III antiarrhythmic agent, on canine models of ventricular arrhythmia. Jpn J Pharmacol 1992; 58: 107-115.
2. Fredrichs GS, Chi L, Gralinski MR, Black SC, Basler GC, Mu DX, et al. MS-551 protects against ventricular fibrillation in a chronic canine model of sudden cardiac death. J Cardiovasc Pharmacol 1995; 25: 314-323.
3. Kamiya J, Ishii M, Yoshihara K, Oyabe A, Banno H, Katakami T. MS-551: Pharmacological profile of a novel class III antiarrhythmic agent. Drug Dev Res 1993; 30: 37-44.
4. Onishi S, Kasanuki H, Shoda M, Matsuda N, Kajimoto K, Umemura J, et al. Efficacy of intravenous doses of MS-551 for drug-resistant sustained ventricular tachycardia. J Clin Therap Med 1997; 13: 1759-1771.
5. Sakurada H, Kobayashi Y, Sugi K, Katagiri T, Baba T, Enjoji Y, et al. Efficacy of intravenous doses of MS-551 for sustained ventricular tachycardia. J Clin Therap Med 1997; 13: 1773-1787.
6. Aonuma K, Hiroe M, Nishimura S, Marumo F. Efficacy of intravenous doses of MS-551 for ventricular tachycardia after myocardial infarction. J Clin Therap Med 1997; 13: 1789-1797.
7. Katoh T, Tsunoo M, Mitsuhashi T, Atarashi H, Ino T, Kuroki S, et al. Phase I study of MS-551 (1) - A single intravenous injection study. J Clin Therap Med 1997; 13: 1659-1674.
8. Nasir N Jr, Taylor A, Doyle TK, Pacifico A. Evaluation of intravenous lidocaine for the termination of sustained monomorphic ventricular tachycardia in patients with coronary artery disease with or without healed myocardial infarction. Am J Cardiol 1994; 74: 1183-1186.
9. Ho DSW, Zecchin RP, Richards DAB, Uther JB, Ross DL. Double-blind trial of lignocaine versus sotalol for acute termination of spontaneous sustained ventricular tachycardia. Lancet 1994; 344: 18-23.
10. Gorgels AP, van den Dool A, Hofs A, Mulleness R, Smeets JLRM, Vos MA, et al. Comparison of procainamide and lidocaine in terminating sustained monomorphic ventricular tachycardia. Am J Cardiol 1996; 78: 43-46.
11. Sahara M, Sagara K, Yamashita T, Iinuma H, Fu LT, Watanabe H. Nifekalant hydrochloride, a novel class III antiarrhythmic agent, suppressed postoperative recurrent ventricular tachycardia in a patient undergoing coronary artery bypass grafting and the Dor approach. Circ J 2003; 67: 712-714.
12. Miyoshi M, Yasuda S, Miyazaki S, Ueno K, Morii I, Otsuka Y, et al. Intravenous administration of nifekalant hydrochloride for the prevention of ischemia-induced ventricular tachyarrhythmia in patients with renal failure undergoing hemodialysis. Circ J 2003; 67: 898-900.
13. Hirose M, Miura M, Wakayama Y, Endo H, Sugai Y, Stuyvers BD, et al. Effect of nifekalant, a class III antiarrhythmic agent, on Ca2+ waves in rat intact trabeculae. Circ J 2005; 69: 739-745.